Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan D Campbell

Showing results (11-20 of 127) with videos related to

Pageof 13
Sort By:
Journal of Comparative Effectiveness Research|March 18, 2026
The inaugural HEMA report: a missed opportunity for comprehensive value assessmentKimberly Westrich, Tyler D Wagner, Jonathan D Campbell
Annals of the American Thoracic Society|February 25, 2014
The "e" in cost-effectiveness analyses. A case study of omalizumab efficacy and effectiveness for cost-effectiveness analysis evidenceJonathan D Campbell, R Brett McQueen, Andrew Briggs
Therapeutic Innovation & Regulatory Science|April 22, 2025
The Inflation Reduction Act and Drug Development: Potential Early Signals of Impact on Post-Approval Clinical TrialsHanke Zheng, Julie A Patterson, Jonathan D Campbell
The American Journal of Managed Care|August 15, 2024
The accelerated approval program for oncology drugs: celebrating more than 250,000 life-years gained and countingJulie Patterson, John Michael O'Brien, Jonathan D Campbell
Journal of General Internal Medicine|October 21, 2015
Societal Implications of Health Insurance Coverage for Medically Necessary Services in the U.S. Transgender Population: A Cost-Effectiveness AnalysisWilliam V Padula, Shiona Heru, Jonathan D Campbell
The European Respiratory Journal|April 30, 2016
Forecasting US ivacaftor outcomes and cost in cystic fibrosis patients with the G551D mutationPiyameth Dilokthornsakul, Ryan N Hansen, Jonathan D Campbell
Health Affairs Scholar|September 2, 2025
Early impact of the Inflation Reduction Act on small molecule vs biologic post-approval oncology trialsHanke Zheng, Julie A Patterson, Jonathan D Campbell
Epilepsy & Behavior : E&B|July 21, 2009
Association between antiepileptic drug switching and epilepsy-related eventsRyan N Hansen, Jonathan D Campbell, Sean D Sullivan
Pharmacoeconomics|July 17, 2023
An Alternative Measure of Health for Value Assessment: The Equal Value Life-YearJonathan D Campbell, Melanie D Whittington, Steven D Pearson
Neurology|January 13, 2022
Performing Cost-Effectiveness Analyses to Support Policy Making: Key Lessons From the Assessment of AducanumabJonathan D Campbell, Melanie D Whittington, Steven D Pearson
Pageof 13

Showing results (11-20 of 127) with videos related to

Sort By:
Pageof 13
Journal of Comparative Effectiveness Research|March 18, 2026
The inaugural HEMA report: a missed opportunity for comprehensive value assessmentKimberly Westrich, Tyler D Wagner, Jonathan D Campbell
Annals of the American Thoracic Society|February 25, 2014
The "e" in cost-effectiveness analyses. A case study of omalizumab efficacy and effectiveness for cost-effectiveness analysis evidenceJonathan D Campbell, R Brett McQueen, Andrew Briggs
Therapeutic Innovation & Regulatory Science|April 22, 2025
The Inflation Reduction Act and Drug Development: Potential Early Signals of Impact on Post-Approval Clinical TrialsHanke Zheng, Julie A Patterson, Jonathan D Campbell
The American Journal of Managed Care|August 15, 2024
The accelerated approval program for oncology drugs: celebrating more than 250,000 life-years gained and countingJulie Patterson, John Michael O'Brien, Jonathan D Campbell
Journal of General Internal Medicine|October 21, 2015
Societal Implications of Health Insurance Coverage for Medically Necessary Services in the U.S. Transgender Population: A Cost-Effectiveness AnalysisWilliam V Padula, Shiona Heru, Jonathan D Campbell
The European Respiratory Journal|April 30, 2016
Forecasting US ivacaftor outcomes and cost in cystic fibrosis patients with the G551D mutationPiyameth Dilokthornsakul, Ryan N Hansen, Jonathan D Campbell
Health Affairs Scholar|September 2, 2025
Early impact of the Inflation Reduction Act on small molecule vs biologic post-approval oncology trialsHanke Zheng, Julie A Patterson, Jonathan D Campbell
Epilepsy & Behavior : E&B|July 21, 2009
Association between antiepileptic drug switching and epilepsy-related eventsRyan N Hansen, Jonathan D Campbell, Sean D Sullivan
Pharmacoeconomics|July 17, 2023
An Alternative Measure of Health for Value Assessment: The Equal Value Life-YearJonathan D Campbell, Melanie D Whittington, Steven D Pearson
Neurology|January 13, 2022
Performing Cost-Effectiveness Analyses to Support Policy Making: Key Lessons From the Assessment of AducanumabJonathan D Campbell, Melanie D Whittington, Steven D Pearson
Pageof 13